Menu
Recruiting NCT07730606

Acute Sodium Bicarbonate Supplementation in Female Basketball Players

Phase III Interventional Supplementation Sports

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Sodium Bicarbonate (NaHCO3), Placebo.
Who it may be relevant to
Registry conditions: Supplementation, Sports. Basic parameters: 16 years — 35 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Poland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation of the Effect of Acute Sodium Bicarbonate Supplementation on Physical Capacity and Blood Biochemical Marker Concentrations in Highly Trained Female Basketball Players

Overview

This randomized, double-blind, placebo-controlled crossover study aims to evaluate the effect of acute sodium bicarbonate supplementation, compared with placebo, on physical capacity and blood biochemical marker concentrations in highly trained female basketball players.

Detailed description

Sodium bicarbonate (SB) is commonly proposed as an ergogenic aid due to its potential to enhance extracellular buffering capacity, thereby supporting acid-base balance and delaying fatigue during repeated high-intensity exercise. This mechanism may be particularly relevant in basketball, where performance depends on repeated short-duration, high-intensity efforts, rapid recovery between actions, and the ability to maintain power output during demanding phases of play. Although the ergogenic effects of SB supplementation have been widely investigated, existing evidence has primarily focused on male participants, and data regarding highly trained female athletes remain limited. This creates an important knowledge gap, especially in team sports such as basketball, where sex-specific physiological responses, training status, and sport-specific demands may influence the effectiveness and tolerability of supplementation strategies. This study will evaluate the effect of a single dose of SB compared with placebo. Participants will receive SB or placebo in a randomized, double-blind, placebo-controlled crossover design. The SB dose will be 0.3 g/kg body mass, administered 90 minutes before the exercise protocol, with intervention visits separated by a washout period. By using a randomized, double-blind, placebo-controlled crossover design, this study will allow for the evaluation of individual responses to acute SB supplementation under controlled laboratory conditions. The findings may help clarify whether acute SB intake is an effective and tolerable strategy for supporting physical capacity and biochemical responses in highly trained female basketball players.

Interventions

  • Dietary supplement Sodium Bicarbonate (NaHCO3)
    Sodium bicarbonate supplementation; Participants will receive a single oral dose of sodium bicarbonate (SB) at 0.3 g/kg body mass, administered in opaque gelatin capsules 90 minutes before the exercise protocol during the first intervention visit.
  • Other Placebo
    Participants will receive a single oral dose of placebo (PL), administered in identical opaque gelatin capsules 90 minutes before the exercise protocol during the first intervention visit.

Primary outcome measures

  • Changes in anaerobic power during the repeated modified Wingate Anaerobic Test [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in interval mean power during the repeated modified Wingate Anaerobic Test [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in second-by-second power output during the repeated modified Wingate Anaerobic Test [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in time to peak power during the repeated modified Wingate Anaerobic Test [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in countermovement jump height [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in countermovement jump power [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in blood bicarbonate, base excess, anion gap, and lactate concentrations [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in hydrogen ion concentration [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in pH in blood [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
Secondary outcome measures (12)
  • Changes in oxygen uptake, carbon dioxide production, and minute ventilation during the repeated modified Wingate Anaerobic Test [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in relative oxygen uptake during the repeated modified Wingate Anaerobic Test [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in respiratory exchange ratio during the repeated modified Wingate Anaerobic Test [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in breathing frequency during the repeated modified Wingate Anaerobic Test [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in tidal volume during the repeated modified Wingate Anaerobic Test [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in heart rate during the exercise protocol [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in rate of perceived exertion [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in gastrointestinal symptoms [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in body mass, fat-free mass, fat mass, total body water, intracellular water, and extracellular water [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in fat-free mass percentage, fat mass percentage, total body water percentage, intracellular water percentage, and extracellular water percentage [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in white blood cell count, white blood cell subpopulations, red blood cell count, and platelet count [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]
  • Changes in hemoglobin concentration [Time frame: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)]

Eligibility criteria

Inclusion criteria

  • female sex,
  • age 16 to 35 years,
  • good general health condition and well-being,
  • regular menstrual cycles,
  • written informed consent to participate in the study before its commencement,
  • at least a high level of training status,
  • at least 4 years of training experience in basketball,
  • participation in at least 3 basketball-specific training sessions per week,
  • participation in at least 1 basketball game per week.

Exclusion criteria

  • male sex,
  • use of hormonal contraceptives,
  • current injury or musculoskeletal condition limiting participation in training or competition,
  • health-related or medical contraindications, including menstrual disorders, planned pregnancy, or anemia,
  • use of supplements within 3 months before the study, except for regular use of protein supplements, carbohydrate supplements, or isotonic drinks,
  • failure to meet the study protocol assumptions or unwillingness to follow study procedures.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Poland · 1 center
  • Department of Sports Dietetics, Poznan University of Physical Education Poznań — Poznan

Identifiers

NCT: NCT07730606 · ZDS_2026_1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗